jbog, you can go back and pick many time frames where MNTA significantly outperforms the IBB. In my view you comments on this topic are meaningless and smell of sour grapes. What matters to each investor is when they bought, and or sold, not looking at a some arbitrary point in time. I first bought in some time after Lovenox was approved, and added or sold more at various points after. The buy I liked best was when we were below $12 and I am up over 25% overall. That number is depressed because I increased my shares of MNTA by 50% after mCopax approval in the $17-19 range.
While I am disappointed that MNTA raised more cash by selling 8 million shares, I am pleased with where I stand now based on what MNTA in its pipeline and marketed or about to be marketed drugs.
Market Data 
Markets 
